Latest:
NYU Scientist Sees Hope Peeking Through Gloom of Glioblastoma
Using a "one-drug-fits-all" approach is not going to be a successful paradigm in a complex disease like glioblastoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Andrew S. Poklepovic, MD
Latest:
VCU Explores Novel Combos for Solid Tumors
Studies conducted at VCU Massey Cancer Center
in Richmond, Virginia, over the past 7 years
have developed the therapeutic combination of
pemetrexed and sorafenib (Nexavar) from
the bench to the bedside, and now into phase II clinical
trial evaluation.
Andrew Stephenson, MD
Latest:
Dr. Stephenson on Patient Preferences on Undergoing Active Surveillance for Prostate Cancer
Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses patient preferences with undergoing active surveillance versus active treatment for their prostate cancer.
Andrew Vassil, MD
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer
Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Andrew X. Zhu, MD
Latest:
Dr. Zhu on Optimal Second-Line Treatment for Patients With HCC
Andrew X. Zhu, MD, PhD, professor of Medicine, Harvard Medical School, director of Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the possibility of an optimal second-line treatment for all patients with hepatocellular carcinoma (HCC).